Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

40.85 +10.74 (+35.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing ↗
Viking Therapeutics (NASDAQ:VKTX) reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much... 
Via MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Q2 Loss Beats Estimates, Shares Edge Lower as Obesity Pipeline Progresses ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗
The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors. 
Via The Motley Fool
News headline image
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗
Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13... 
Via MarketBeat
News headline image
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗
Both companies are approaching milestones that could light a fire under their stocks. 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
This company aims to serve a market heading toward $100 billion. 
Via The Motley Fool
News headline image
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗
Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company. 
Via The Motley Fool
News headline image
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong ↗
Viking Therapeutics deserves a second look, but some analysts are a bit too optimistic. 
Via The Motley Fool
News headline image
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. ↗
The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate. 
Via The Motley Fool
News headline image
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? ↗
Investor sentiment on the key benefit of its lead drug candidate could be impacted in the current quarter. 
Via The Motley Fool
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
They are fairly risky, but their potential upside is massive. 
Via The Motley Fool
News headline image
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗
It's not much of a rivalry yet. 
Via The Motley Fool
News headline image
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished ↗
In a slow news month for the company, investors focused on the cost of its phase 3 trials rather than their benefits. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
There are other reasons to pay attention to Viking Therapeutics. 
Via The Motley Fool
News headline image
Viking Therapeutics Stock Moves Lower: What's Going On? ↗
Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know. 
Via Benzinga
News headline image
Viking Therapeutics Q2 Earnings Call Highlights ↗
Viking Therapeutics (NASDAQ:VKTX) reported a wider second-quarter loss as the company increased spending to advance its obesity pipeline, including its lead dual GLP-1/GIP receptor agonist, VK2735,... 
Via MarketBeat
Topics Earnings
News headline image
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case ↗
The stock looks like a high-risk, high-reward play. 
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
Viking's latest program seeks to push the envelope in weight loss efficacy. 
Via The Motley Fool
News headline image
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." ↗
Wall Street analysts are highly bullish on Viking Therapeutics, not least because of its promising weight-loss drug, with ongoing and upcoming phase 3 trials. 
Via The Motley Fool
News headline image
This GLP-1 Stock Could Double by 2030. Here's Why ↗
Investors need to ask tough questions before initiating a position in this biotech company. 
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
There are good reasons to invest in Lilly and to hold off. 
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years ↗
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an annualized basis producing an average annual return of 40.15%. Currently, Viking Therapeutics has a... 
Via Benzinga
News headline image
Is This Biotech Stock a Buy After Its Massive Rally? ↗
This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the payoff arrives. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Eli Lilly? ↗
The stock has soared 400% in recent years. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.